Esperion Therapeutics Inc. (NASDAQ:ESPR) saw unusually-strong trading volume on Tuesday . Approximately 820,535 shares changed hands during mid-day trading, an increase of 169% from the previous session’s volume of 304,522 shares.The stock last traded at $13.49 and had previously closed at $11.44.

Several equities analysts have recently commented on the stock. JMP Securities reaffirmed a “buy” rating and set a $67.00 price target on shares of Esperion Therapeutics in a research report on Thursday, June 16th. Credit Suisse Group AG cut shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and reduced their price target for the stock from $23.00 to $10.00 in a research report on Wednesday, June 29th. JPMorgan Chase & Co. cut shares of Esperion Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $50.00 to $15.00 in a research report on Wednesday, June 29th. Royal Bank Of Canada cut shares of Esperion Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $30.00 to $15.00 in a research report on Wednesday, June 29th. Finally, Lake Street Capital reduced their price target on shares of Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating on the stock in a research report on Wednesday, June 29th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $24.40.

The company’s 50 day moving average is $10.98 and its 200 day moving average is $14.25. The stock’s market cap is $304.65 million.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.16. During the same quarter in the prior year, the company posted ($0.55) earnings per share. Equities research analysts forecast that Esperion Therapeutics Inc. will post ($3.37) EPS for the current fiscal year.

In other news, Director Mark E. Mcgovern bought 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 6th. The shares were purchased at an average price of $10.00 per share, for a total transaction of $50,000.00. Following the acquisition, the director now directly owns 600 shares of the company’s stock, valued at approximately $6,000. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 35.40% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in ESPR. Rhenman & Partners Asset Management AB increased its position in shares of Esperion Therapeutics by 50.0% in the first quarter. Rhenman & Partners Asset Management AB now owns 150,000 shares of the biopharmaceutical company’s stock valued at $2,537,000 after buying an additional 50,000 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of Esperion Therapeutics by 1.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 330,950 shares of the biopharmaceutical company’s stock valued at $5,596,000 after buying an additional 4,471 shares during the period. Geode Capital Management LLC increased its position in shares of Esperion Therapeutics by 17.8% in the first quarter. Geode Capital Management LLC now owns 107,392 shares of the biopharmaceutical company’s stock valued at $1,815,000 after buying an additional 16,208 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of Esperion Therapeutics during the first quarter valued at approximately $313,000. Finally, A.R.T. Advisors LLC increased its position in shares of Esperion Therapeutics by 93.6% in the first quarter. A.R.T. Advisors LLC now owns 200,858 shares of the biopharmaceutical company’s stock valued at $3,396,000 after buying an additional 97,112 shares during the period. Hedge funds and other institutional investors own 65.22% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

5 Day Chart for NASDAQ:ESPR

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.